Six items have been removed from the reimbursement list after reimbursement reevaluations during the past 4 years. Silymarin bilberry fruit dried powder, followed by itopride, failed the reimbursement reevaluations. Streptokinase - streptodornase, oxiracetam, and acetylcarnitine were also removed due to reimbursement reevaluation failures. Pharmaceutical companies are facing annual losses of up to KRW 240 billion as a result of the 6 drugs' reimbursement reevaluation failures.

According to the Ministry of Health and Welfare on the 14th, 55 itopride-based drugs have been removed from the reimbursement list as of this month.

The move follows the government's reimbursement revaluation. The he